1. Home
  2. WT1-Related Wilms Tumor Syndromes

WT1-Related Wilms Tumor Syndromes
Symptoms, Doctors, Treatments, Advances & More

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

WT1-Related Wilms Tumor Syndromes Overview

  • Top Doctors
  • Latest Advances
  • Clinical Trials
Save information for later
Sign Up

Learn About WT1-Related Wilms Tumor Syndromes

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top WT1-Related Wilms Tumor Syndromes Local Doctors?
Richard M. Vanlangendonck
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Richard M. Vanlangendonck
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Richard M. Vanlangendonck
Urology

Heber Valley Specialty Clinic - Urology

Heber City, UT 
435-657-4600
Experience:
30+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Vanlangendonck, MD is a urologist at Intermountain Health’s Heber Valley Specialty Clinic in Hever City, Utah, and Jerry & Kathleen Grundhofer Clinic – Urology in Park City, Utah. He supports patients in Park City, Snyderville, Kamas, Francis, Woodland, Heber City, and surrounding communities, treating prostate cancer, kidney cancer, adrenal cancer, bladder cancer, and more. His clinical interests focus on robotic surgery for the treatment of prostate and kidney cancer. He is passionate about this technology's advanced capabilities, allowing for precise and minimally invasive procedures that significantly benefit his patients. Dr. Vanlangendonck is deeply committed to providing his patients with the highest standard of care. Guided by his philosophy of being the best doctor and person he can be, he treats each individual with compassion and respect. Committed to excellence, the Louisiana native continually strives to perfect his craft. He takes great pride in delivering outstanding patient care and ensuring that each patient is satisfied.Potential patients should know that Dr. Vanlangendonck excels in his field and is passionate about his expertise. He brings this expertise to his practice every day, providing his patients with the highest level of care and support throughout their wellness journey.Conditions Treated: Prostate CancerKidney CancerAdrenal CancerBladder CancerKidney and Ureteral StonesBenign Prostatic Hyperplasia Elevated PSAVoiding Dysfunction Erectile DysfunctionProcedures Performed: Robotic Urologic Surgery for Urologic Cancers Robotic Urologic Surgery for Urinary Obstruction Ureteroscopy Transurethral Surgery for Bening and Malignant DiseaseCystoscopyTransrectal and Transperineal Ultrasound with Prostate BiopsyVasectomy. Dr. Vanlangendonck is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Reconstructive Urology Surgery, and Nephrectomy. Dr. Vanlangendonck is board certified in American Board Of Urology. Dr. Vanlangendonck is currently accepting new patients.

Song Zhao
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Song Zhao
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Song Zhao
Oncology

Medical Oncology - Swedish Cancer Institute First Hill

1221 Madison Street, 
Seattle, WA 
206-386-3751
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Zhao believes in providing the best cancer care through multidisciplinary, evidence-based — yet personalized — approaches. Dr. Zhao is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Variegate Porphyria, Hereditary Coproporphyria, Porphyria, and Prostate Cancer. Dr. Zhao is board certified in American Board Of Internal Medicine. Dr. Zhao is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Jerry X. Liu
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jerry X. Liu
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jerry X. Liu
Hematology | Oncology

Advocate Infusion Center

525 E Congress Pkwy, Ste 300, 
Crystal Lake, IL 
815-759-9260
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jerry Liu is a Hematologist and an Oncologist practicing medicine in Crystal Lake, Illinois. Dr. Liu is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 44 other conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Colorectal Cancer, Familial Colorectal Cancer, Anemia, and Bone Marrow Aspiration. Dr. Liu is board certified in American Board Of Internal Medicine, Hematology.

View All Doctors
What are the Latest Advances for WT1-Related Wilms Tumor Syndromes?
Study of High Levels of Wilms' Tumor 1 (WT1) Expression in Ovarian Cancers.
Study of High Levels of Wilms' Tumor 1 (WT1) Expression in Ovarian Cancers.
Journal: Cureus
Published: March 01, 2026
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine.
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine.
Journal: Journal for immunotherapy of cancer
Published: July 15, 2025
Tired of the same old research?
Check Latest Advances
Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.
Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.
Journal: Bone marrow transplantation
Published: July 07, 2025
View All Latest Advances
What are the latest WT1-Related Wilms Tumor Syndromes Clinical Trials?
Match to trials
Find the right clinical trials for you in under a minute
Get started
View All Clinical Trials
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved